Eris Lifesciences - 2QFY19 – Acquisitions Drive Top Line Much Higher, Bottom Line to Follow by FY20E
Eris Lifesciences (ERIS IN) reported lower than expected performance in 2QFY19. Revenues were 5% lower than our estimates at Rs 2,642 mn. The...
414 Views
ERIS Lifesciences – FY18 Annual Report Analysis - Strong Rebound in Cash Flow Likely from FY19E
We reviewed the FY18 Annual Report of Eris Lifesciences (ERIS IN). Eris reported the negative free cash flow of ~Rs 3,148 mn due to business...
450 Views
Eris Lifesciences - 1QFY19 – Strides Assimilation on Track
Eris Lifesciences (ERIS IN) reported revenue growth of 35% YoY to Rs 2.5 bn (+18% QoQ), EBITDA growth of 24% YoY to Rs 886 mn (+23% QoQ) and...
278 Views
Eris Lifesciences Ltd - Q4FY18 Beats Expectations, FY19E on Track
Eris Lifesciences Limited (ERIS IN) reported Q4FY18 results recently. Performance Highlights Eris reported Q4FY18 consolidated revenues at Rs 2.1...
113 Views
ERIS Lifesciences Limited – Acquisition Led Growth Story
Eris Lifesciences Limited (ERIS IN) is engaged in the marketing and manufacturing of branded generic drugs and derives all its revenues from the...
232 Views